Newbury Pharmaceuticals AB (publ) (STO:NEWBRY)
Sweden flag Sweden · Delayed Price · Currency is SEK
3.130
+0.050 (1.62%)
Apr 30, 2025, 9:17 AM CET

STO:NEWBRY Cash Flow Statement

Millions SEK. Fiscal year is Sep - Aug.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Feb '25 Aug '24 Aug '23 Aug '22 Aug '21
Net Income
-13.41-15.41-19.43-14.67-6.06
Depreciation & Amortization
0.960.820.340.09-
Asset Writedown & Restructuring Costs
0.910.910.910.910.66
Stock-Based Compensation
-0.09-0.090.070.15-
Other Operating Activities
-1.01-0.130.25-0.13-
Change in Accounts Receivable
-7.07-7.07-11.161.26-2.1
Change in Inventory
-2.89-2.89-0.33-1.77-
Change in Other Net Operating Assets
10.960.146.12-0.853.07
Operating Cash Flow
-11.63-23.71-23.23-15-4.44
Sale (Purchase) of Intangibles
-0.15-2.91-0.86-24.4-25.18
Investment in Securities
-0.05-0.05---3.98
Investing Cash Flow
-0.2-2.95-0.86-24.4-29.17
Long-Term Debt Issued
-17.31-21.78-
Long-Term Debt Repaid
--2.03-0.72-7.13-
Net Debt Issued (Repaid)
15.2715.27-0.7214.64-
Issuance of Common Stock
18.1618.16-44.9547.94
Financing Cash Flow
18.2833.44-0.7259.5947.94
Net Cash Flow
6.456.78-24.8120.1914.34
Levered Free Cash Flow
-4.66-4.46-21.63-31.69-
Unlevered Free Cash Flow
-3.55-3.5-21.63-31.69-
Change in Net Working Capital
-3.53-7.729.86-1.2-
Source: S&P Global Market Intelligence. Standard template. Financial Sources.